Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CM336 in Relapsed or Refractory Multiple Myeloma
NCT05299424Phase 2Recruiting
- Sponsor
- Keymed Biosciences
- Start
- Aug 2022
- Primary completion
- Dec 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of gamgertamig in multiple myeloma (MM) (2 arms), sponsored by Keymed Biosciences. Primary endpoints: Dose-limiting toxicities at 21 days, Adverse events up to 4.5 years and 1 more. Started Aug 2022; status: recruiting.
02
Drugs
gamgertamig
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05299424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05299424.